Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

This study is testing a combination of carboplatin, a taxane (paclitaxel or docetaxel), and ramucirumab (a drug that blocks blood vessel growth) for people with advanced non-squamous non-small cell lung cancer whose disease progressed after an initial treatment regimen including pemetrexed and/or pembrolizumab maintenance. **You may be eligible if...** - You are 18 years or older - You have advanced or recurrent non-squamous non-small cell lung cancer - You have previously received 4–6 cycles of pemetrexed/carboplatin/pembrolizumab and then progressed after at least 18 weeks of maintenance therapy - You are in good physical condition (ECOG 0–1) - You do not have a targetable mutation (such as EGFR or ALK) that has an approved targeted therapy **You may NOT be eligible if...** - You have a driver mutation eligible for targeted therapy - You have another active cancer requiring treatment - You have significant nerve damage (grade 2 or higher peripheral neuropathy) - You have untreated brain metastases - You have a history of serious bleeding Talk to your doctor to see if this trial is right for you.